ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 645

Subclinical Cardiovascular Involvement in Patients with Primary Sjögren Syndrome

Alberto Batticciotto1, Federica Rigamonti1, Fabiola Atzeni1, Marco Antivalle1, Rossella Talotta1, Laura Boccassini1, Luigi Gianturco2, Maurizio Turiel2, Andrea Doria3 and Piercarlo Sarzi-Puttini1, 1Rheumatology Unit, L. Sacco University Hospital, Milano, Italy, 2Cardiology Unit, IRCCS-Galeazzi Orthopedic Institute, Milan, Italy, 3Department of Medicine-DIMED, University of Padova, Padova, Italy

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Sjogren's syndrome and cardiovascular disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Sjögren's Syndrome Poster I: Clinical Insights into Sjögren's Syndrome

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Different studies showed that systemic inflammation, elevated levels of inflammatory cytokines and immune dysregulation, typical of the inflammatory autoimmune disease, play a role in accelerated atherosclerosis. However, only few studies focused on sub-clinical cardiovascular (CV) involvement in patients with primary Sjögren’s syndrome (pSS) are available (1). Aim of our study was to investigate sub-clinical CV involvement in pSS patients by means of carotid stiffness, asymmetric dimethyl arginine (ADMA) plasma levels, intima-media thickness (cIMT) and coronary flow reserve (CFR). 

Methods:

Fifty-three consecutive outpatients with pSS (7 M, 46 F; mean age 59.8 yrs, range 43-80 yrs; mean disease duration of 59.5 months, range 6-156 months) without classical CV risk factors and/or known CV diseases, and 22 matched healthy controls were enrolled. MyLab 60 machine (Esaote,Italy) with radio frequency technology for evaluating quality intima media thickness (RF-QIMT) and quality arterial stiffness (RF-QAS) was used to assess cIMT and pulse wave velocity (PWV), respectively. Dipyridamole transthoracic stress echocardiography was performed by IE33 (Philips Medical Systems, USA) in order to obtain CFR values. Plasma ADMA levels, inflammatory markers and autoantibodies were also evaluated. 

Results:

pSS group was matched with control in terms of age (59.8±8.5 vs 59.25±2.08 yrs, p=0.14), sex (46F, 7M vs 16F, 6M, p=0.8), BMI (25.5±3.3 vs 23.69±1.12. p=0.17) and blood pressure values (126.66±13.4 vs 125.61±12.48, p=0.59 and 79.4±4.6 vs 80.45±8.25. p=0.32). Serum levels of CRP (3.72±2.89 Vs 0.41±0.09 mg/L, p<0.0001), ESR (30.25±20.2 Vs 4.8±0.24, p<0.0001) and, although within the normal range, total cholesterol (182.77±7.12 Vs 163.33±5.59, p<0.001) were significantly lower in the control group. PWV and ADMA plasma levels, as markers of subclinical atherosclerosis and endothelial dysfunction respectively, were significantly higher (9.2±1.8m/s vs 6.8±0.9m/s. p<0.0001 and 0.76±0.07 vs 0.54±0.05 μM, p<0.0001) in pSS group. QIMT values were similar in the two groups; however, the percentage of pSS patients with abnormal value was higher compared with controls (47/53 vs 12/22, p=0.001). Although within the normal range, CFR values in pSS patients were lower than in controls (2.6±0.23 vs 3.2±0.32 p<0.0001). 

Conclusion:

Higher ADMA levels, higher PWV values, higher percentage of patients with pathological Q-IMT and normal CFR values, suggested that pSS patients compared to healthy controls suffer from early endothelial dysfunction and sub-clinical atherosclerosis.


Disclosure: A. Batticciotto, None; F. Rigamonti, None; F. Atzeni, None; M. Antivalle, None; R. Talotta, None; L. Boccassini, None; L. Gianturco, None; M. Turiel, None; A. Doria, None; P. Sarzi-Puttini, None.

To cite this abstract in AMA style:

Batticciotto A, Rigamonti F, Atzeni F, Antivalle M, Talotta R, Boccassini L, Gianturco L, Turiel M, Doria A, Sarzi-Puttini P. Subclinical Cardiovascular Involvement in Patients with Primary Sjögren Syndrome [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/subclinical-cardiovascular-involvement-in-patients-with-primary-sjogren-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/subclinical-cardiovascular-involvement-in-patients-with-primary-sjogren-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology